Beam Therapeutics Quarterly Cash Flow Statement
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beam Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Beam Therapeutics generated -$66.1 million of operating cash flow and spent $2.4 million on capital expenditures. That left free cash flow of -$68.5 million, a free-cash-flow margin of -13981.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Beam Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -122.68M | -94.32M | 244.30M | -113.82M | -102.14M | -108.33M | -90.35M | -96.67M | -91.05M | -98.67M | 142.80M | -96.09M |
| Net Income growth (YoY) | — | — | — | — | — | — | -163.27% | — | — | — | — | — |
| Depreciation & Amortization | 5.41M | 5.61M | 5.67M | 5.56M | 5.54M | 5.53M | 5.44M | 5.47M | 5.58M | 5.43M | 5.36M | 5.19M |
| Stock-Based Compensation | 19.28M | 19.04M | 20.45M | 22.75M | 24.37M | 26.68M | 30.22M | 29.56M | 31.60M | 29.28M | 22.62M | 25.84M |
| Change in Working Capital | 30.44M | -36.00M | -112.57M | -5.63M | -3.05M | -3.63M | -13.42M | -12.22M | -3.25M | -11.16M | -97.89M | -23.80M |
| Operating Cash Flow | -66.10M | -128.51M | -83.29M | -81.48M | -76.45M | -103.88M | -76.36M | -88.13M | -83.01M | -99.75M | 135.07M | -89.78M |
| Capital Expenditures | -2.41M | -2.23M | -3.73M | -5.01M | -3.14M | -3.06M | -2.97M | -1.58M | -1.96M | -2.44M | -3.59M | -7.95M |
| Investing Cash Flow | -9.88M | 25.27M | 108.41M | 65.66M | -170.41M | -125.09M | 126.28M | 24.70M | 87.49M | -53.46M | 98.10M | -10.23M |
| Debt Issued | 0 | 93.89M | — | — | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 7.52M | 96.61M | 1.89M | 1.68M | 1.11M | 473.38M | 3.44M | 1.26M | 133.00K | 2.90M | 33.71M | 36.78M |
| Net Change in Cash | -68.45M | -6.64M | 27.00M | -14.15M | -245.75M | 244.41M | 53.36M | -62.16M | 4.62M | -150.31M | 266.88M | -63.24M |
| Free Cash Flow | -68.51M | -130.75M | -87.02M | -86.49M | -79.59M | -106.95M | -79.33M | -89.70M | -84.97M | -102.19M | 131.48M | -97.73M |
This table shows 12 quarterly periods of Beam Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BEAM's reporting calendar. What is a cash flow statement?